Predicting Outcomes in Hypoglossal Nerve Stimulation Therapy With Stimulated Upper Airway Mechanics

Sleep Apnea, Obstructive Clinical Trial

Official title:

Assessing Stimulated Upper Airway Mechanics to Predict Outcomes in Hypoglossal Nerve

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05429983
• Other study ID #: IRB00319723
• Secondary ID: 278-jf-22
• Status: Recruiting
• Start date: November 29, 2022
• Est. completion date: November 29, 2025

Study information

• Verified date: November 2023
• Source: Johns Hopkins University
• Contact: Kevin M Motz
• Phone: 410614245
• Email: kmotz1[@]jh.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Obstructive sleep apnea (OSA) is a highly prevalent disease resulting from dynamic upper airway collapse during sleep. Continuous positive airway pressure (CPAP) is highly efficacious but high rates of non-adherence to CPAP leaves large number of OSA patients at risk for cardiometabolic sequelae. Inspire™ is an FDA-approved hypoglossal nerve stimulation device (HGNS) used in select patients with OSA who are intolerant of CPAP. The device consists of an implanted impulse generator with a stimulating cuff lead around the distal hypoglossal nerve. Despite these stringent selection criteria, up to one-third of patients implanted have inadequate responses to HGNS and remain at risk for complications from untreated OSA. The current proposal builds on routine clinical care to characterize upper airway biomechanics and determine predictors of clinical responses to HGNS therapy. Drug induced sleep endoscopy (DISE) is a prerequisite for HGNS treatment and represents an ideal opportunity to rapidly characterize upper airway dynamics under controlled, standardized conditions. The amount of nasal pressure required to relieve airway obstruction (minimal therapeutic pressure) is a significant predictor of successful treatment of OSA with HGNS. As a result, CPAP titration (measuring pharyngeal collapse patterns at varying nasal pressures) has become an integral part of DISE to select parties for HGNS at multiple institutions. Nevertheless, changes in upper airway collapsibility in response HGNS may differ significantly between patients. This stud will examine if changes in upper airway patency with direct genioglossus muscle stimulation at the time of DISE predicts successful treatment with HGNS as defined by a 50% reduction on apnea-hypopnea index (AHI) and an on-treatment AHI <20.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: November 29, 2025
• Est. primary completion date: November 29, 2024
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male and female participants with moderate or severe sleep apnea (defined by > 15 apneas and hypopneas per hour of sleep), who are undergoing DISE as part of routine evaluation for Inspire hypoglossal nerve stimulation therapy or for ineffective HGNS therapy.

Exclusion Criteria:

• Significant cardiac disease, unstable or recent cardiac events
• Active pulmonary, liver or renal disease
• Uncontrolled hypertension (BP>160/100)
• Neuromuscular disease
• Major psychiatric disease
• Pregnancy
• Anticoagulation therapy (e.g. Coumadin, Dabigatran)

Related Conditions & MeSH terms

• Sleep Apnea, Obstructive

Locations

Country	Name	City	State
United States	Johns Hopkins Hospital	Baltimore	Maryland

Sponsors (2)

Lead Sponsor	Collaborator
Johns Hopkins University	American Academy of Sleep Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Tidal airflow with direct genioglossus stimulation	Tidal airflow (mL) with direct stimulation of the genioglossus muscle will be measured at the time of drug-induced sleep endoscopy.	at the time of drug-induced sleep endoscopy, up to 1 hour
Primary	HGNS therapy success as assessed by the apnea hypopnea index	Successful treatment with HGNS, as defined by a 50% reduction in apnea hypopnea index (AHI) and an on-therapy AHI of <15 (the same criteria as in major trials of non-CPAP OSA treatment).	at 1 year post HGNS implantation
Secondary	Therapeutic CPAP pressure with direct genioglossus stimulation	Therapeutic CPAP pressure (cmH20) with direct stimulation of the genioglossus muscle will be measured at the time of drug-induced sleep endoscopy.	At the time of drug-induced sleep endoscopy, up to 1 hour
Secondary	Airway critical closing pressure with direct genioglossus stimulation	Airway critical closing pressure (cmH20) with direct stimulation of the genioglossus muscle will be measured at the time of drug-induced sleep endoscopy.	At the time of drug-induced sleep endoscopy, up to 1 hour